Comments
Sun Pharmaceutical Industries Ltd has announced that the USFDA has granted approval for its subsidiary for its Abbreviated New Drug Application (ANDA) to market a generic version of Sumatriptan Succinate injection, 6 mg (base)/0.5ml.
According to the company, this is the first ANDA approval for a Sumatriptan AutoInjector. Annual sale for Sumatriptan Succinate injections in the US is approximately $190 million.
Sumatriptan Succinate injection is indicated for the acute treatment of migraine attacks with or without aura and acute treatment of cluster headache episodes.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.